Musculoskeletal evaluation in severe haemophilia A patients from Latin America

Summary There is a paucity of literature on haemophilia treatment in Latin American countries, a region characterized by rapidly improving systems of care, but with substantial disparities in treatment between countries. The aim of this study was to evaluate the musculoskeletal status of haemophilia...

Full description

Saved in:
Bibliographic Details
Published in:Haemophilia : the official journal of the World Federation of Hemophilia 2014-01, Vol.20 (1), p.e63-e70
Main Authors: Ozelo, M. C., Villaça, P. R., Pérez-Bianco, R., Candela, M., Garcia-Chavez, J., Moreno-Rodriguez, B., Rodrigues, M. B., Rodriguez-Grecco, I., Solano, M. H., Chumpitaz, G., Morales-Gana, M. M., Ruiz-Sáez, A.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age Factors
Aged
Child
Child, Preschool
Factor VIII - administration & dosage
Factor VIII - therapeutic use
haemophilia
haemophilia treatment
haemophilic arthropathy
Hemarthrosis - diagnosis
Hemarthrosis - etiology
Hemarthrosis - therapy
Hemophilia A - complications
Hemophilia A - drug therapy
Humans
Latin America
Male
Middle Aged
musculoskeletal evaluation
Original
Premedication
Severity of Illness Index
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary There is a paucity of literature on haemophilia treatment in Latin American countries, a region characterized by rapidly improving systems of care, but with substantial disparities in treatment between countries. The aim of this study was to evaluate the musculoskeletal status of haemophilia patients from Latin America and to examine the relationship between musculoskeletal status and treatment practices across countries. The Committee of Latin America on the Therapeutics of Inhibitor Groups conducted a survey of its member country representatives on key aspects of haemophilia treatment in 10 countries. Musculoskeletal status of patients was obtained during routine comprehensive evaluations between March 2009 and March 2011. Eligible patients had severe haemophilia A (factor VIII
ISSN:1351-8216
1365-2516
DOI:10.1111/hae.12316